The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
Open accessAbstract
PURPOSE: To determine the predictive and prognostic value of the consensus molecular subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene expression–based features largely in primary tumors from six independent classification systems and provide a framework for capturing the intrinsic heterogeneity of CRC in patients enrolled in CALGB/SWOG 80405. PATIENTS AND METHODS: CALGB/SWOG 80405 is a phase III trial that compared the addition of bevacizumab or cetuximab to infusional fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan as first-line treatment of advanced CRC. We characterized the CMS classification using a novel NanoString gene expression panel on primary CRCs from 581 patients enrolled in this study to assess the prognostic and predictive value of CMSs in these patients. RESULTS: The CMSs are highly prognostic for overall survival (OS; P < .001) and progression-free survival (PFS; P < .001). Furthermore, CMSs were predictive for both OS ( P for interaction < .001) and PFS ( P for interaction = .0032). In the CMS1 cohort, patients treated with bevacizumab had a significantly longer OS than those treated with cetuximab ( P < .001). In the CMS2 cohort, patients treated with cetuximab had a significantly longer OS than patients treated with bevacizumab ( P = .0046). CONCLUSION: These findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy as part of the initial treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“bevacizumab is effective regardless of RAS gene status”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other
Mann, H. B., & Whitney, D. R. (1947) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177730491 · Cited by 14,320
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationColorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Cancer treatment and survivorship statistics, 2012
Siegel, R. L., Desantis, C. E., Virgo, K. S., Stein, K., Mariotto, A. B., Smith, T. G., Cooper, D. L., Gansler, T. S., Lerro, C. C., Fedewa, S. A., et al. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,979
Cancer treatment and survivorship statistics, 2014
Desantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,847
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Flagged first, then by citations
Research works printed but not linked: 1
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Sorted by citations
Items 201–247 of 247
COLORECTAL MOLECULAR SUBTYPES – PROGRESS OR DEADLOCK?
Fedyanin, M. Y., Ignatova, E. O., & Tryakin, А. А. (2021) · Practical oncology · doi:10.31917/2201072 · Cited by 1
METASTATİK KOLON KANSERİ TEDAVİSİNDEKİ YENİLİKLER
Karabulut, S., Karabulut, M., & Taştekin, D. (2021) · Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi · doi:10.26650/iuitfd.2020.0086 · Cited by 1
Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020
Siebenhüner, A. R. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.05.017 · Cited by 1
Development of Machine Learning based Colorectal Cancer Subtype Classificator
Kulcsar, F., Bekevari, D., Eigner, G., Drexler, D. A., Patai, Á. V., Micsík, T., & Fleiner, R. (2021) · IEEE International Symposium on Computational Intelligence and Informatics (CINTI) · doi:10.1109/cinti53070.2021.9668384 · Cited by 1
Utilising Proteomics and Organoid Cultures for Predicting Treatment Response in Colorectal Cancer
Micallef, I., & Baron, B. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106028 · Cited by 1
Rotermund, A., Staege, M. S., Brandt, S., Luetzkendorf, J., Lucas, H., Mueller, L. P., & Mueller, T. (2023) · Cancers · doi:10.3390/cancers15164122 · Cited by 1
Qiu, L., Chen, S., Ben, S., Cui, J., Lü, S., Qu, R., Lv, J., Shao, W., & Yu, Q. (2024) · Cancer Medicine · doi:10.1002/cam4.6996 · Cited by 1
Xuan, T., Wang, Z., Meng, S., Li, J., Li, J., Cao, F., & Qu, L. (2024) · Cancer Management and Research · doi:10.2147/cmar.s443666 · Cited by 1
Liu, C., Zhong, C., Liu, H., Peng, W., Liao, Z., & Wu, C. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00422 · Cited by 1
Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome
Yazıcı, O., Uçar, G., Sütçüoğlu, O., Turhal, N. S., Yıldız, B., Karamouzis, M. V., Yavuz, S., Karadurmuş, N., Zengin, N., Geva, R., et al. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2037848 · Cited by 1
Greene, M. W., Abraham, P., Kuhlers, P. C., Lipke, E. A., Heslin, M. J., Wijaya, S. T., & Odeniyi, I. A. (2021) · medRxiv · doi:10.1101/2021.08.31.21262900 · Cited by 1
Cayún, J. P., Cerpa, L. C., Colombo, A., Cáceres, D., Leal, J. L., Reyes, F., Gutiérrez-Cáceres, C., Calfunao, S., Varela, N., & Quiñones, L. A. (2023) · Preprints.org · doi:10.20944/preprints202307.0972.v1 · Cited by 1
Alig, A. H. S., Heinemann, V., Geißler, M., von Weikersthal, L. F., Decker, T. W., Heinrich, K., Held, S., Weiss, L., Fischer, L. E., Moosmann, N., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-219007/v1
A roadmap for medical treatment of metastatic CRC
Martínez-Bernal, G., Martínez‐Pérez, J., & Valladares‐Ayerbes, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00016-8
Single-Cell Atlas of Infiltrating B Cells and Their Clinical Outcomes in Colorectal CancerPreprint
Xia, J., Xie, Z., Niu, G., Zhou, L., Wang, Z., Xing, Y., Ren, J., Hu, Z., Hong, R., Cao, Z., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3960668
Wu, Q., Wang, H., Zhang, S., Zeng, Y., Yang, W., Pan, W., Hong, G., & Gao, W. (2022) · Research Square · doi:10.21203/rs.3.rs-1600353/v1
Innocenti, F., Yazdani, A., Rashid, N. U., Qu, X., Ou, F., Buren, S. V., Bertagnolli, M. M., Kabbarah, O., Blanke, C. D., Venook, A. P., et al. (2023) · doi:10.1158/1078-0432.c.6532436
Self-citationNguyen, H.-Q., Tran, K.-L., Vuong, M.-H., Tran, Q.-T., & Ho, X. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16034-9.00005-8
Kreis, J., Aybey, B., Geist, F., Brors, B., & Staub, E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.25.554747
Huang, H., He, X., Zhang, Q., Li, J., Ye, Y., Rong, H., & Xueqin, Y. (2021) · International Journal of Cancer and Clinical Research · doi:10.23937/2378-3419/1410160
Uema, R., Hayashi, Y., Komori, M., Shibukawa, N., Hayashi, N., Horimoto, M., Yamada, T., Yamamoto, M., Hiyama, S., Kinoshita, K., et al. (2023) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000649
Adachi, T., Shimomura, M., Egi, H., Shimizu, W., Takakura, Y., Mukai, S., Kochi, M., Yoshimitsu, M., Hinoi, T., & Ohdan, H. (2023) · Cureus · doi:10.7759/cureus.50431
Afrăsânie, V.-A. (2024) · The Medical-Surgical Journal · doi:10.22551/msj.2024.01.02
Molecular Biomarkers in Colorectal Cancer in the Era of Precision Medicine: A Review
Colombo, A., Gebbia, V., Borsellino, N., & Porretto, C. M. (2024) · International Journal of Advanced Multidisciplinary Research and Studies · doi:10.62225/2583049x.2024.4.3.2738
Jiang, T., Chen, H., Wang, X., Lin, F.-Y., Wang, H., Liu, J., & Lin, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1425203
Is the transverse colon the new right?—similarities in EGFR drug response and prognosis
Cameselle‐García, S., & Montés, A. F. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-272
New Insights on Success and Failed Drugs
Sun, Z., & Zhou, Y. (2024) · Springer eBooks · doi:10.1007/978-981-97-7274-2_10
Clinical Characteristics of and Treatment Pattern for EGFR-Amplified Colorectal Cancer
Kim, S.-E., Jeong, H., Kim, J. E., Kim, D., Hong, Y. S., Kim, D., Kim, T., Lee, J. S., & Kim, T. W. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2024.569
Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen
Gamal, D. A., Morsy, A., & Omar, M. (2025) · Oncotarget · doi:10.18632/oncotarget.28687
Novel treatment-specific causal biomarkers for colorectal cancer by omics integration
Yazdani, A., Yazdani, A., Méndez-Giráldez, R., Pillonetto, G., Samiei, E., Hadi, R., Lenz, H., Venook, A. P., Samiei, A., Nixon, A. B., et al. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaf053
Self-citationNeurobiology of suicidal behavior in females: concerning immune systems and blood hormones-II
Kundu, S. R., & Sarkar, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33112-1.00014-8
Treatment Modalities, Targeted Therapies, and Immunotherapy in Metastatic Colorectal Cancer
Karakullukcu, M., & Şenocak, D. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1012530
Oki, E., Shinto, E., Shimokawa, M., Yamaguchi, S., Ishiguro, M., Hasegawa, S., Takii, Y., Ishida, H., Kusumoto, T., Morita, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17204856
Kim, J., Kim, H., Lee, M.-S., Lee, H., Kim, Y. J., Lee, W. Y., Yun, S. H., Kim, H. C., Hong, H. K., Hannenhalli, S. S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26576252
Moosavi, S. H., Eide, P. W., Eilertsen, I. A., Brunsell, T. H., Berg, K. C. G., Røsok, B. I., Brudvik, K. W., Bjørnbeth, B. A., Guren, M. G., Nesbakken, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16557287
Wu, Q., Wang, H., Zhang, S., Zeng, Y., Yang, W., Pan, W., Hong, G., & Gao, W. (2022) · Figshare · doi:10.6084/m9.figshare.20488709
KIM, J., Kim, H., Lee, M.-S., Lee, H., Kim, Y. J., Lee, W. Y., Yun, S. H., Kim, H. C., Hong, H. K., Hannenhalli, S. S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26576255
Oki, E., Shinto, E., Shimokawa, M., Yamaguchi, S., 石黒, め., Hasegawa, S., Takii, Y., Hideyuki, I., Kusumoto, T., Morita, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17204859
Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12922094
Yang, M., Schell, M. J., Salk, J. J., Higgins, J. E., Hipp, M. J., Pflieger, L. T., Pledger, W. J., & Yeatman, T. J. (2026) · Cellular Oncology · doi:10.1007/s13402-025-01140-y
Cheng, X.-F. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i5.115009 · Cited by 1
Fan, Z., Mei, Y., Liu, K., Zhang, Y., & Shi, L. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156613
Madurga, S., López-Blanco, D., Foguet, C., Lahoz, S., Oliveres, H., Moreno, R., Gorría, T., Pedrosa, L., Marín, S., Rojas, M., et al. (2026) · Biology · doi:10.3390/biology15141128
Cross-Cohort Evaluation of NanoString nCounter Data for Recurrence Prediction in Colorectal CancerPreprint
van Ufford, P. Q., Bojesen, R. D., Olsen, L. R., Gögenür, I., & Lund, O. (2026) · medRxiv · doi:10.64898/2026.08.13.26360359
Beyond a binary RTK-RAS biomarker: context-aware precision oncology in early-onset colorectal cancer
Velazquez-Villarreal, E. I. (2026) · Journal of Cancer Biology · doi:10.46439/cancerbiology.7.085
Liang, L., Lin, H., & Jun, L. (2026) · Acta Histochemica · doi:10.1016/j.acthis.2026.152377
Metadata
- Authors
- Lenz, H.-J., Ou, F.-S., Venook, A. P., Hochster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Bertagnolli, M. M., Blanke, C. D., Zemla, T., Qu, X., Wirapati, P., Tejpar, S., Innocenti, F., & Kabbarah, O.
- Affiliations
- USC Norris Comprehensive Cancer Center (US)
- Mayo Clinic (US)
- University of California, San Francisco (US)
- Yale Cancer Center, New Haven, CT
- Duke Medical Center (US)
- West Virginia University (US)
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Oregon Health & Science University (US)
- Genentech (US)
- SIB Swiss Institute of Bioinformatics (CH)
- Universitair Ziekenhuis Leuven (BE)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2019-08-01
- Volume
- 37
- Issue
- 22
- Pages
- 1876-1885
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC6675593
- OpenAlex
- W2943196840
- Cited by
- 246
- References
- 35
- Citations by year
- 2026: 11 · 2025: 31 · 2024: 28 · 2023: 27 · 2022: 39 · 2021: 61 · 2020: 37 · 2019: 8
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-02-07)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Pfizer
- Bayer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Teva Pharmaceutical Industries
- Baxalta
- Taiho Pharmaceutical
- Exelixis
- Jazz Pharmaceuticals
- Leidos
- BeiGene
- Incyte
- Eisai
- National Institutes of Health (UL1TR001863)
- Genentech
- Takeda Oncology
- Pharmacyclics
- National Cancer Institute (U10CA180882, U10CA180820, U10CA180791, UG1CA233290, U10CA180888, U10CA180836, U10CA180790, UG1CA233331, UG1CA233180, U10CA180830, U10CA180795, U10CA180850, U10CA180838, U10CA180867, U10CA180821, UG1CA180830, U10CA180799)
- National Institute of General Medical Sciences (U54GM104942)
- National Center for Advancing Translational Sciences
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- consensus molecular subtypes, metastatic colorectal cancer, prognostic factors, predictive biomarkers, bevacizumab, cetuximab, first-line chemotherapy, overall survival, progression-free survival, targeted therapy selection
- MeSH terms
- Bevacizumab, Cetuximab, Irinotecan, Oxaliplatin, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Predictive Value of Tests, Prognosis, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Treatment Outcome, Disease-Free Survival, Gene Expression Profiling, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
